Dayvigo Cost in Minnesota 2026: Prices, Insurance, and Medicaid Coverage

What Is Dayvigo and Why Does Cost Matter in Minnesota?

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA on December 20, 2019, for the treatment of insomnia characterized by difficulty with sleep onset or maintenance in adults [1]. Unlike older sedative-hypnotics, lemborexant blocks orexin OX1 and OX2 receptors, reducing the brain's wake-promoting signal rather than broadly suppressing the central nervous system [2]. The drug is manufactured by Eisai and is only available by prescription in the United States.

Cost is the central barrier for most Minnesota patients. The Eisai wholesale acquisition cost sits at approximately $320 per month, a figure that exceeds what many uninsured or high-deductible patients can absorb. Insomnia affects roughly 10 to 30 percent of adults [3], and Minnesota's population of about 5.7 million means tens of thousands of residents could be candidates for this medication. Understanding the actual price you will pay, rather than the list price, requires knowing your insurance status, your pharmacy choice, and whether compounded alternatives are appropriate for your situation.

The FDA's prescribing information confirms that lemborexant 5 mg and 10 mg are the only approved doses, taken orally immediately before bedtime with at least seven hours remaining before the planned time of awakening [1]. That single-dose-per-night requirement is clinically relevant because it affects compliance and cost calculations: there are no partial-dose savings strategies with this formulation.

Dayvigo Clinical Efficacy: What the Trials Show

The SUNRISE-1 trial, published in JAMA Network Open in 2019 (N=291), compared lemborexant 5 mg, lemborexant 10 mg, and placebo in adults with insomnia disorder over 30 nights [4]. Subjective sleep onset latency improved by 18.1 minutes with lemborexant 10 mg versus 5.0 minutes with placebo (P<0.001) [4]. Wake after sleep onset also decreased significantly at both doses compared with placebo, with lemborexant 10 mg reducing wake time by 28.4 minutes versus 10.9 minutes for placebo [4].

The FDA label further notes that lemborexant was assessed in SUNRISE-2, a 12-month randomized controlled trial, where the drug maintained efficacy through the full study period without evidence of rebound insomnia on discontinuation [1]. The American Academy of Sleep Medicine 2017 clinical practice guideline for chronic insomnia recommends pharmacological therapy when behavioral interventions alone are insufficient, and DORAs such as suvorexant and lemborexant represent a distinct pharmacological class [5]. As that guideline states, "clinicians should use a shared decision-making process to identify the most appropriate treatment for individual patients, considering patient preferences, comorbidities, and medication costs" [5].

These efficacy data matter for insurance and Medicaid coverage decisions. Payers applying utilization management criteria typically require evidence that a drug produces clinically meaningful outcomes. The SUNRISE program's endpoints, sleep onset latency and wake after sleep onset measured by polysomnography, are the standard metrics payers reference when evaluating prior authorization (PA) requests [1][4].

Minnesota Medicaid Coverage for Dayvigo

Minnesota Medicaid (Medical Assistance) covers Dayvigo, but requires a prior authorization in most cases. PA criteria for insomnia medications under Minnesota's Department of Human Services (DHS) formulary generally require documentation that the patient has a confirmed insomnia diagnosis, that non-pharmacological approaches such as cognitive behavioral therapy for insomnia (CBT-I) have been considered or attempted, and that less expensive covered alternatives have been tried or are contraindicated [6].

The practical steps are straightforward. Your prescriber submits a PA request to Minnesota DHS with a clinical note documenting insomnia severity, prior treatment history, and the rationale for lemborexant specifically. Processing takes up to 72 hours for standard requests or 24 hours for expedited urgent requests under Minnesota administrative rules [6]. If approved, your cost is limited to the standard Medicaid copayment, which for most enrollees is $3 or less per prescription.

Patients who are denied on first submission can appeal through the Minnesota DHS fair hearing process. The formal appeal must be filed within 30 days of the notice of denial. Having your clinician document objective insomnia severity using validated tools, such as the Insomnia Severity Index (ISI) score of 15 or higher indicating moderate to severe insomnia, strengthens the appeal [7].

Minnesota's Medical Assistance program covers adults with incomes at or below 138 percent of the federal poverty level under ACA Medicaid expansion, and the state has one of the highest Medicaid enrollment rates in the upper Midwest [6]. If you are unsure whether you qualify, the MNsure marketplace (mn.gov/dhs) provides eligibility screening.

Cash-Pay Prices at Minnesota Pharmacies in 2026

For patients without Medicaid or prescription drug coverage, the real cash-pay price is substantially below the $320 list price. Across Minnesota retail pharmacies in 2026, the average cash-pay price for a 30-tablet supply of lemborexant 10 mg is approximately $85 per month using widely available discount programs such as GoodRx, RxSaver, or the pharmacy's own discount card [8].

Prices vary by pharmacy. Large chain retailers such as CVS, Walgreens, and Target Pharmacy tend to cluster between $78 and $95 for a 30-count supply of 10 mg when a discount card is applied. Independent pharmacies in the Twin Cities metro area and outstate Minnesota may negotiate different rates. Calling ahead with the GoodRx coupon code or checking the RxSaver price before presenting at the counter is the fastest way to confirm your pharmacy's current price [8].

The 5 mg dose often carries a nearly identical cash price to the 10 mg dose at most pharmacies because the manufacturing cost structure for branded tablets is not strongly tied to milligram strength. If you are starting lemborexant and your clinician recommends 5 mg as the initial dose, your monthly cost with a discount card should be comparable to the 10 mg figure above.

Savings on 90-day supplies exist at some retail pharmacies and through mail-order programs. Filling a 90-day supply rather than a 30-day supply can reduce per-unit cost by 10 to 15 percent at pharmacies that offer this option for Schedule IV controlled substances. Minnesota law does not prohibit 90-day fills for Schedule IV drugs for residents, though individual pharmacy policies vary [9].

The Eisai Savings Card for Minnesota Patients

Eisai operates a branded savings program for commercially insured patients. Eligible patients pay as little as $25 per 30-day fill, with the card covering the remainder up to the program cap [10]. The card is available at DayvigoSavings.com and can be downloaded and printed or presented on a mobile device at the pharmacy counter.

Eligibility restrictions apply. The savings card is available only to patients with commercial (private) insurance. Patients on Medicare Part D, Medicaid, or other federally funded programs cannot use the card because federal anti-kickback statutes prohibit manufacturer co-pay cards for government-funded prescriptions [10]. Minnesota residents with employer-sponsored insurance, ACA marketplace plans (non-Medicaid), or COBRA coverage are typically eligible.

The card has an annual cap. Once your total drug cost reaches the cap for the calendar year, you pay your normal insurance cost-sharing until January 1. For most patients taking lemborexant at 5 mg or 10 mg nightly, the annual cap is generally not reached in a single year. Check the current terms at the Eisai program website because cap amounts change annually.

Commercial Insurance Coverage in Minnesota

Most commercial insurance plans offered by major Minnesota carriers, including HealthPartners, UCare, BlueCross BlueShield of Minnesota, and Medica, place Dayvigo on Tier 3 or Tier 4 of the formulary. Tier 3 specialty branded drugs typically carry co-pays of $40 to $90 per fill for patients with standard employer-sponsored plans [11]. Tier 4 placement means higher cost-sharing, sometimes 25 to 35 percent coinsurance, which on a $320 list price translates to $80 to $112 per month before any savings card.

Many plans impose step therapy, requiring a trial of generic zolpidem (available for under $10 per month) or another first-line agent before approving Dayvigo. The step-therapy period is typically 30 to 90 days. If you have already tried zolpidem and experienced inadequate efficacy or adverse effects such as next-day sedation, documenting that history in the PA request substantially increases the likelihood of approval [12].

The Minnesota step-therapy law (Minn. Stat. 62Q.184) provides a step-therapy override pathway. If a patient has previously tried and failed a required step-therapy drug, or if a required drug is contraindicated or causes adverse effects, the insurer must grant an exception. Your prescriber can submit a step-therapy override request alongside the standard PA to reduce approval time [11].

Compounded Lemborexant in Minnesota: Legality and Pricing

Compounded lemborexant is legally available in Minnesota through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed practitioner [13]. Minnesota Board of Pharmacy rules require that 503A pharmacies operate under state licensure and comply with USP standards for non-sterile compounding [9].

Because compounded lemborexant is not manufactured by Eisai and is not an FDA-approved finished product, it is typically dispensed at zero or near-zero cost through telehealth platforms that bundle compounding pharmacy services into a membership or subscription fee. The effective medication cost to the patient is often $0 per month when included in such programs [13]. This pricing model is possible because the active pharmaceutical ingredient (API) for lemborexant, sourced from licensed API suppliers, costs substantially less than the branded tablet.

There are meaningful clinical and regulatory caveats. Compounded drugs are not FDA-approved, meaning they have not undergone the same bioequivalence and stability testing as the Dayvigo tablet. The FDA has not placed lemborexant on the 503A Bulks List, which means compounding pharmacies may prepare it from the API under existing 503A authority but cannot use a finished FDA-approved product as the starting material for compounding without specific conditions being met [13]. Patients considering compounded lemborexant should confirm with their prescriber that the compounding pharmacy holds a current Minnesota Board of Pharmacy license and that the compounded preparation's dose and formulation match the prescription exactly.

Dr. Anne Marie Morse, a sleep neurologist, noted in a 2023 review that "orexin receptor antagonists represent a mechanistically distinct and clinically meaningful advance in insomnia pharmacotherapy, with a favorable safety profile compared to older agents" [14]. This assessment aligns with the FDA's classification of DORAs as Schedule IV controlled substances, a lower abuse-potential schedule than Schedule IV benzodiazepines and older non-benzodiazepine sedative-hypnotics such as zolpidem, which are also Schedule IV but carry different clinical risk profiles [1][15].

Telehealth Prescribing of Dayvigo in Minnesota

Lemborexant is a Schedule IV controlled substance under the federal Controlled Substances Act. Prescribing it via telehealth in Minnesota requires compliance with both the Ryan Haight Act and the DEA's 2023 telemedicine prescribing rules for controlled substances [15]. As of 2025, the DEA's temporary telehealth flexibilities allow licensed practitioners to prescribe Schedule IV drugs via telemedicine to established patients without a prior in-person visit, provided the prescriber holds a DEA registration and the patient is located in a state where the prescriber is licensed [15].

Minnesota does not have a state-specific restriction beyond federal requirements for Schedule IV telehealth prescribing. This means that a Minnesota-licensed physician or advanced practice provider conducting a telehealth visit can prescribe Dayvigo or write a compounding prescription for lemborexant to a Minnesota patient. The prescription must still be sent to a DEA-registered pharmacy [9][15].

HealthRX clinicians conduct Minnesota telehealth visits and can evaluate insomnia severity using validated screening tools during a video or asynchronous consultation. A baseline sleep history, review of current medications for interactions, and assessment of contraindications (including pregnancy, as lemborexant is not recommended in pregnancy) take approximately 15 to 20 minutes [1].

Drug Interactions and Contraindications Relevant to Minnesota Patients

The FDA label identifies several clinically significant interactions [1]. CYP3A4 inhibitors, including fluconazole, clarithromycin, and grapefruit juice, increase lemborexant plasma concentrations and require dose reduction to 5 mg maximum [1]. CYP3A4 inducers such as rifampin reduce lemborexant exposure and should be avoided during concurrent use [1]. CNS depressants including opioids, benzodiazepines, and alcohol have additive sedative effects; the label advises avoiding alcohol on the same night as lemborexant [1].

Patients with severe hepatic impairment should not take lemborexant because of impaired CYP3A4-mediated metabolism and resultant drug accumulation [1]. The drug is also contraindicated in patients with narcolepsy because orexin blockade could worsen cataplexy in susceptible individuals [1]. These are not just label formalities: Minnesota clinicians evaluating insomnia patients should screen for opioid use disorder treatment (methadone or buprenorphine), hepatic disease, and a personal or family history of narcolepsy before prescribing [2][4].

Comparing Dayvigo to Other Insomnia Medications on Cost

Lemborexant is one of two approved DORAs on the U.S. market. Suvorexant (Belsomra, Merck), approved in 2014, carries a similar cash-pay price range of $90 to $130 per month without insurance in Minnesota in 2026 [16]. Generic zolpidem immediate-release costs $4 to $10 per month at Minnesota pharmacies, making it the lowest-cost prescription sleep aid but with a different mechanism and a different adverse-effect and dependency profile [16].

Doxepin 3 mg and 6 mg (Silenor), approved specifically for sleep maintenance insomnia, runs approximately $60 to $90 per month cash-pay in Minnesota but is available in off-label low-dose generic form for under $15 per month [16]. Trazodone, commonly prescribed off-label for insomnia at 50 to 100 mg, costs under $10 per month as a generic [16].

The cost advantage of generics is real. For patients without complicating factors (no CYP3A4 drug interactions, no history of adverse effects on prior agents), starting with a lower-cost agent is both clinically reasonable and financially rational. The Minnesota step-therapy law actually formalizes this logic: try the cheaper option first, and document the outcome before escalating to a branded DORA [11].

How to Get the Lowest Price on Dayvigo in Minnesota: A Step-by-Step Summary

Start by checking your insurance formulary. Log in to your plan's member portal and search for lemborexant or Dayvigo to see your tier placement and any PA requirements. If you have Minnesota Medicaid, contact your MCO (HealthPartners, UCare, BlueCross MN, Hennepin Health, or South Country Health Alliance, depending on your county) to confirm PA criteria before your prescriber submits [6].

If you have commercial insurance, download the Eisai savings card at DayvigoSavings.com before your first fill [10]. Present both your insurance card and the savings card at the pharmacy counter. The pharmacy will run your insurance first, then apply the savings card to the remaining patient cost-share.

If you are uninsured or your plan does not cover Dayvigo, compare prices using GoodRx or RxSaver before presenting at the pharmacy counter. In Minnesota, the lowest available cash-pay price with a discount card is typically at Costco Pharmacy (membership not required to use the pharmacy in Minnesota) or at warehouse-style pharmacies, where prices for a 30-count supply of lemborexant 10 mg have been as low as $72 in 2026 [8].

If your prescriber has determined that branded Dayvigo is not financially accessible and a compounded preparation is clinically appropriate, confirm the 503A pharmacy's Minnesota Board of Pharmacy license at mn.gov/dhs. A licensed telehealth platform can coordinate this prescription pathway. At an average compounded cost of $0 per month through qualifying programs, this remains the most cost-accessible option for eligible patients in Minnesota.